药物信息为ERY-TAB (KAISER FOUNDATION HOSPITALS): Pregnancy
- DESCRIPTION
- CLINICAL PHARMACOLOGY
- Microbiology
- INDICATIONS AND USAGE
- CONTRAINDICATIONS
- WARNINGS
- PRECAUTIONS
- Information for Patients
- Drug Interactions
- Drug/Laboratory Test Interactions
- Carcinogenesis, Mutagenesis, Impairment of Fertility
- Pregnancy
- Labor and Delivery
- Nursing Mothers
- Pediatric Use
- ADVERSE REACTIONS
- OVERDOSAGE
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- Recommended Storage
- 外部链接相关的ERY-TAB (KAISER FOUNDATION HOSPITALS)
- Teratogenic effectsPregnancy Category B
There is no evidence of teratogenicity or any other adverse effect on reproduction in female rats fed erythromycin base (up to 0.25 percent of diet) prior to and during mating, during gestation, and through weaning of two successive litters. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
- Drug Information Provided by National Library of Medicine (NLM).
